How to Get Repatha (Evolocumab) in the District of Columbia

What Is Repatha and Why DC Patients Are Prescribed It

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), the protein responsible for degrading LDL receptors on liver cells. By blocking PCSK9, evolocumab keeps more LDL receptors active on hepatocyte surfaces, allowing the liver to clear substantially more LDL-C from circulation [1].

The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and adults with established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering on top of diet and maximally tolerated statin therapy [2]. The approved subcutaneous doses are 140 mg every two weeks or 420 mg once monthly for most indications; patients with HoFH receive 420 mg monthly [2].

The landmark FOURIER trial (N=27,564 patients with established ASCVD on high-intensity statin therapy) found that evolocumab reduced LDL-C by a median of 59% from a baseline of 92 mg/dL, bringing median on-treatment LDL-C to 30 mg/dL [3]. The primary composite endpoint of cardiovascular death, myocardial infarction, stroke, unstable angina hospitalization, or coronary revascularization was reduced by 15% (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) over a median follow-up of 2.2 years [3]. Secondary endpoint analysis showed a 20% reduction in the harder composite of cardiovascular death, MI, or stroke (HR 0.80; 95% CI 0.73 to 0.88; P<0.001) [3].

DC cardiologists and internists prescribe Repatha most often for patients with LDL-C that remains above 70 mg/dL despite maximally tolerated statin therapy, for those who are statin-intolerant, and for patients with confirmed FH whose baseline LDL-C may be 190 mg/dL or higher [4].

Who Can Prescribe Repatha in the District of Columbia

Any licensed prescriber with DC prescribing authority may write a Repatha prescription. That includes MDs, DOs, nurse practitioners (NPs) with DC licensure, and physician assistants (PAs) licensed by the DC Board of Medicine [5].

NPs in Washington, DC practice under full practice authority as of 2018, meaning they may diagnose, treat, and prescribe Schedule II through V controlled substances without a physician supervisory agreement [5]. Repatha is not a controlled substance, so NPs face no additional barriers. PAs still require a written practice agreement with a supervising physician for prescribing in DC, though that requirement does not restrict which non-controlled medications they may prescribe within their scope [5].

Telehealth prescribing is permitted in DC provided a valid prescriber-patient relationship exists. The DC Department of Health does not require an in-person visit before a telehealth prescriber issues a non-controlled prescription, which means a board-certified lipidologist or cardiologist practicing via telehealth and licensed in DC may prescribe Repatha after a synchronous video visit that includes review of labs, cardiac history, and a statin trial record [6].

HealthRX connects DC residents with physicians and NPs licensed in the District for exactly this type of consultation. A typical telehealth visit reviews the patient's lipid panel, medication history, and cardiovascular risk before transmitting a prescription electronically to a DC-licensed specialty pharmacy.

Lab Work Required Before a DC Provider Will Prescribe Repatha

A fasting lipid panel is the minimum required before any prescriber will initiate evolocumab. Most DC prescribers and virtually all insurance prior authorizations require results dated within 90 days [7].

The standard pre-prescription labs include:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)
• Liver function tests (AST, ALT), particularly if high-intensity statin therapy is ongoing
• CK (creatine kinase) if statin myopathy is suspected or if the patient is statin-intolerant
• HbA1c or fasting glucose for patients with metabolic risk factors, since PCSK9 inhibition has a modest association with new-onset diabetes noted in some analyses [8]

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "For patients with clinical ASCVD in whom LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe. If LDL-C remains 70 mg/dL or higher, adding a PCSK9 inhibitor is reasonable (Class IIa, LOE: A)" [4]. Bringing a printed copy of this guideline language to your insurer's PA reviewer can reduce back-and-forth significantly.

If you have a known FH diagnosis, genetic testing results (variants in LDLR, APOB, or PCSK9 genes) or a documented Dutch Lipid Clinic Network score of 6 or higher strengthen the prior authorization submission considerably [9].

How Prior Authorization Works for Repatha in DC

Prior authorization (PA) is the single largest source of delay for DC patients seeking Repatha. Both commercial plans operating in DC and DC Medicaid (administered by DC Department of Health Care Finance) require PA before dispensing [10].

The standard PA documentation package for DC insurers typically includes:

1. Diagnosis code confirming HeFH, HoFH, or established ASCVD (ICD-10: E78.01, E78.02, or I25.10)
2. Most recent fasting LDL-C result with date
3. Evidence of a trial of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 90 days, OR documentation of statin intolerance with CK values or muscle biopsy if available
4. Evidence that ezetimibe 10 mg was tried and either failed to achieve target LDL-C or was not tolerated
5. Letter of medical necessity from the prescribing physician or NP

DC Medicaid covers evolocumab with PA for patients with FH or established ASCVD [10]. The DC Medicaid preferred drug list does not currently designate a PCSK9 inhibitor as non-preferred, which means the PA process follows standard medical necessity criteria rather than requiring a step-through a competing agent within the same class [10].

Commercial insurer timelines in DC average 3 to 7 business days for standard PA and 24 to 72 hours for urgent PA when a cardiologist documents imminent cardiovascular risk. If PA is denied, DC residents have the right to an internal appeal within 60 days and an external independent review under DC Code 31-3512 [11].

Amgen's copay card program (Repatha SupportPlus) may reduce out-of-pocket costs to as low as zero dollars per month for commercially insured patients who qualify; DC Medicaid and Medicare Part D beneficiaries are not eligible for manufacturer copay assistance but may qualify for the Amgen patient assistance program [12].

Telehealth Providers in DC Prescribing Repatha

Telehealth is a legal and practical pathway to a Repatha prescription in Washington, DC. The District's telehealth statute (DC Code 31-3861) defines telehealth broadly to include synchronous audio-video communication, and DC-licensed providers may use telehealth to initiate new prescriptions for non-controlled medications [6].

A typical HealthRX telehealth workflow for DC patients runs as follows. The patient completes an online intake form with cardiovascular history, current medications, and LDL-C goals. Lab results are uploaded or ordered through a DC-area LabCorp or Quest Diagnostics draw site. A licensed DC physician or NP conducts a 20 to 30-minute synchronous video visit to confirm the indication, review contraindications, and discuss injection technique. The prescription is sent electronically to a specialty pharmacy licensed to ship to DC addresses.

Repatha must be kept refrigerated (36 to 46°F). Several specialty pharmacies operating in DC, including CVS Specialty, Walgreens Specialty, and Accredo, ship evolocumab in insulated packaging with ice packs to maintain the cold chain during transit [13]. Patients who prefer in-person pickup can use any DC-licensed specialty pharmacy with a refrigerated dispensing unit.

The single-use SureClick autoinjector (140 mg/mL) and the Pushtronex on-body infusor (420 mg/3.5 mL) are both available from DC pharmacies; the Pushtronex is the preferred monthly dosing device for patients who want once-monthly rather than biweekly administration [2].

Repatha Prescription Transfer to or from DC

Transferring an existing Repatha prescription to a DC pharmacy is straightforward. Federal law and DC pharmacy regulations permit the transfer of non-controlled prescriptions between licensed pharmacies an unlimited number of times as long as refills remain on the original prescription [14]. Controlled substance transfer rules (maximum one transfer in most states) do not apply to Repatha.

To transfer, the patient calls or electronically contacts the receiving DC pharmacy, provides the current pharmacy name and phone number, and the pharmacies coordinate the transfer directly. Because Repatha is typically dispensed in 28-day or 84-day supplies from specialty pharmacies, patients moving to DC should time the transfer so that at least two weeks of supply remain at the time of the request, allowing for insurance reauthorization in DC if the plan changes [14].

Patients switching DC insurance plans at open enrollment should re-verify PA status with the new insurer before their current supply runs out. A lapse of more than 30 days in evolocumab therapy does not require retitration, but LDL-C will begin rising within weeks of discontinuation since the drug's mechanism is reversible [15].

Monitoring After Starting Repatha in DC

Once therapy begins, most DC lipid specialists check a fasting lipid panel 4 to 12 weeks after the first injection to confirm the expected 50 to 60% LDL-C reduction [4]. The ACC/AHA 2022 guideline recommends rechecking lipids 4 to 12 weeks after any intensification of LDL-lowering therapy [4].

Long-term monitoring is minimal compared to statins. The FOURIER open-label extension (FOURIER-OLE) followed 6,635 patients for up to 8.4 years and found no new safety signals, no meaningful change in liver enzymes, and no excess neurocognitive adverse events attributable to very low achieved LDL-C levels [16]. Patients who achieved LDL-C below 20 mg/dL showed continued cardiovascular benefit without evidence of harm [16].

Annual fasting lipid panels are sufficient for stable patients on evolocumab monotherapy or evolocumab plus statin. Patients on concurrent high-intensity statin should continue any statin-related monitoring (periodic CK if symptomatic, LFTs if clinically indicated) per standard statin guidelines [17].

Injection site reactions occur in approximately 2.1% of evolocumab-treated patients versus 1.6% of placebo in FOURIER [3]. Rotating injection sites (abdomen, thigh, upper arm) and allowing the autoinjector to reach room temperature for 30 minutes before use reduce local discomfort.

503A Compounding of Evolocumab in DC

503A compounding pharmacies in DC are licensed by the DC Board of Pharmacy and operate under USP 797 standards for sterile preparations [18]. Technically, a 503A pharmacy could compound a PCSK9 inhibitor formulation for an individual patient with a valid prescription, but this is rarely done and carries important caveats.

Evolocumab is a large, complex biologic monoclonal antibody. The FDA has not placed it on the 503A bulk drug substances list because a commercially available FDA-approved version exists [19]. Compounded biologics are not substitutable for FDA-approved reference products under the Biologics Price Competition and Innovation Act, and no compounded evolocumab formulation has undergone the clinical trials that established Repatha's cardiovascular outcomes benefit [3]. For patients seeking LDL-C reduction tied to a reduction in MI and stroke, the FDA-approved Amgen product is the appropriate choice.

Compounded small-molecule bempedoic acid or extended-release niacin may occasionally appear as alternatives at DC 503A pharmacies, but neither has the outcomes data behind evolocumab [20]. The 2022 ACC/AHA guideline gives PCSK9 inhibitors a Class IIa Level A recommendation for high-risk ASCVD patients, a designation that compounded alternatives have not earned [4].

Cost and Insurance Coverage in DC

Without insurance, a 28-day supply of Repatha 140 mg/mL autoinjectors retails for approximately $650 to $700 at DC pharmacies, based on current GoodRx estimates. Few patients pay list price.

DC commercial insurers covering evolocumab include most Blue Cross Blue Shield plans operating in the DC market, Aetna, United Healthcare, and CareFirst. Each requires PA. Tiering varies: some plans place Repatha on a specialty tier with a flat 20% coinsurance; others use fixed copays of $50 to $150 per 28-day supply after deductible [10].

DC Medicaid covers evolocumab under the preferred drug list with PA, as noted above. Copays for DC Medicaid beneficiaries are nominal (typically $3 to $4 per prescription for name-brand drugs) [10].

Medicare Part D beneficiaries in DC should be aware that as of 2025, the Inflation Reduction Act caps out-of-pocket specialty drug costs at $2,000 per year under Part D, which substantially reduces the net cost for patients who previously faced high specialty tiers [21].

Patients who remain uninsured or underinsured should contact Amgen's dedicated enrollment line for the Repatha patient assistance program, which provides the drug at no cost to qualifying individuals with incomes below 600% of the federal poverty level [12].

Getting Started: The Step-by-Step Path for DC Residents

The fastest path from today to a first Repatha injection in DC follows this sequence. Order or locate a fasting lipid panel dated within the last 90 days. Gather documentation of any prior statin trials, including drug names, doses, and duration. Book a telehealth or in-person visit with a DC-licensed prescriber (cardiologist, lipidologist, internist, NP, or PA with supervising physician agreement). At the visit, confirm indication, review contraindications, and obtain an e-prescription. The prescriber's office submits PA paperwork to your insurer simultaneously. Upon PA approval, the specialty pharmacy ships Repatha to your DC address in temperature-controlled packaging. First injection typically occurs 7 to 21 days after the initial consult, with the shorter end of that range common when labs are already in hand and PA is approved on first submission.

Patients with prior ASCVD events (MI, stroke, or coronary revascularization) may qualify for expedited PA under urgent medical necessity criteria, potentially compressing the timeline to 3 to 5 days [4].

A fasting LDL-C check at 8 weeks after the first dose confirms response. The ACC/AHA guideline target for very high-risk ASCVD patients is LDL-C below 70 mg/dL; for patients with multiple high-risk features, a target below 55 mg/dL is reasonable [4].